Activities
  1. 【著作】胥博懷弁護士が、月刊 ザ・ローヤーズ 2014年11月号において、『台湾での日系企業IPO(新規上場)の利点』を執筆しました(弁護士法人 第一法律事務所山本和人弁護士と共著)。
  2. 【公共参加】当事務所の蔡嘉政弁護士及び程威居弁護士は、東呉大学の法科大学院で開催される模擬法廷コンテストに参加する学生たちの訴訟実務経験の指導者として招かれました。
  3. 【講演活動】当事務所の盧偉銘弁護士が2013年11月29日に世新大学の会社法科目で「企業合併と買収実務事例」の講演に招かれます。
  4. 【公共参加】当事務所の盧偉銘弁護士、羅祖芳弁護士及び張琬婷弁護士が2013年11月20日に国立台湾大学の法科大学院で開催される「法曹のキャリアプラン講座~多元的な法曹像」に座長として出席します。
  5. 【公共参加】当事務所の蔡嘉政弁護士が2013年11月19日に東呉大学で「法曹のキャリアプラン講座」の講演に招かれます。
  6. 【講演活動】 当事務所の盧偉銘弁護士は2013年7月20日、台北律師公会 (Taipei Bar Association) 公司治理及企業併購委員会 (コーポレートガバナンスおよび企業買収合併委員会) を主宰し、世新大学法学院の胡韶雯助理教授をお招きし、「コーポレートガバナンスに関する法制度の改正と実務的発展」という題で講演をしていただきました。
  7. 【講演活動】 当事務所の盧偉銘弁護士は2013年6月22日、台北律師公会 (Taipei Bar Association) 公司治理及企業併購委員会 (コーポレートガバナンスおよび企業買収合併委員会) を主宰し、台湾大学法学院の邵慶平副教授をお招きし、「企業における証券取引法と侵権行為法の交錯 ― 裁判所による実務上の見解を例に」という題で講演をしていただきました。
  8. 【公共参加】 当事務所の盧偉銘弁護士、李師栄弁護士及び劉孟哲弁護士が、2013年5月30日に国立政治大学で開催された「法曹のキャリアプラン講座~多元的な法曹像」懇談会にパネリストとして?出席しました。
  9. 【公共参加】 当事務所の劉孟哲弁護士が、2013年4月17日に中華民国証券投資信託及び顧問商業協同組合に同行して北京中国証券監督管理委員会及び国家外国為替管理局を訪問しました。
  10. 【教育訓練】当事務所は、2013年3月29日、国立政治大学法学大学院の林佳和助教授を招いて「労働法規に関する問題の解析及び法改正の動向」を開催しました。
  11. 【公共参加】 当事務所の盧偉銘弁護士、蔡嘉政弁護士及び張君珮弁護士は2013年3月20日、国立台北大学で開催される「学生キャリアシリーズ講座 ― 『典型』と『非典型』の対話」と題するフォーラムに出席します。
  12. 【講演活動】 当事務所の劉康身弁護士が、財団法人生物技術開発センターの招待を受けたため、2013年3月14日、「個人情報保護法の施行細則及び企業がどうのように対応していくか」という講演を開きます。
  13. 【講演活動】 当事務所の劉孟哲弁護士は2012年7月24日社団法人台湾理財顧問認証協会の招待を受け、2013年3月12日に「金融サービス業における個人情報保護法施行のポイント及び法的責任」という題で講演を行いました。
  14. 【教育訓練】 当事務所は、2013年1月16日、林鈺雄教授を招いて「大法廷制度の特定テーマ講演」を開きました。
  15. 【講演活動】 当事務所の蔡嘉政弁護士が台北弁護士協会から2013年1月11日に「第二世代国民健康保険説明会」の座長として招かれました。
  16. 【教育訓練】 当事務所は、2013年1月8日、謝銘洋教授を招いて「特許新法に関する問題の探究及び評価分析-兼我が国における現行の知的財産法制に関する問題を論じる」を開きました。
  17. 【講演活動】 当事務所の盧偉銘弁護士は、会社組織研究発展協会から2012年11月29日に「企業コンプライアンス及び取締役会の秘書役のベストな実務フォーラム」におけるパネリストとしての出席依頼を受けました。
  18. 【研究計画】当事務所は中華民国証券投資信託および顧問商業同業公会 (SECURITIES INVESTMENT TRUST & CONSULTING ASSOCIATION OF THE R.O.C.) の委託を受け、「在台ファンドはいかに中国市場に参入販売するかに関する研究」について研究し、研究報告を提供しています。
  19. 【講演活動】 当事務所の盧偉銘弁護士は2012年11月24日、台北律師公会 (Taipei Bar Association) 公司治理及企業併購委員会 (コーポレート・ガバナンスおよび企業買収合併委員会) を主宰し、朱德芳副教授をお招きして「インサイダー取引の規範における最新の発展」と題してご講演いただきます。
  20. 【講演活動】 当事務所の盧偉銘弁護士は2012年10月13日、台北律師公会 (Taipei Bar Association) 公司治理及企業併購委員会 (コーポレートガバナンスおよび企業買収合併委員会) を主宰し、林仁光教授をお招きして「変動中のコーポレート・ガバナンス-ポスト世界金融危機の改革」と題してご講演いただきます。
  21. 【講演活動】 当事務所の盧偉銘弁護士ならびに劉孟哲弁護士は2012年8月16日、行政院金融監督管理委員会証券期貨局に招かれ、「外国口座税務コンプライアンス法 (FATCA) 規定の資産管理業者に対する影響について」と題して講演を行いました。
  22. 【講演活動】 当事務所の盧偉銘弁護士は2012年8月4日、台北律師公会 (Taipei Bar Association) に、「弁護士が裁判所から管理人、清算人などの職務に選任された際に直面する困難および不合理な扱いに関する問題座談会」のパネリストとして招かれました。
  23. 【講演活動】 当事務所の盧偉銘弁護士、劉孟哲弁護士ならびに頼宛瑩弁護士は2012年7月24日、中華民国証券投資信託および顧問商業同業公会 (SECURITIES INVESTMENT TRUST & CONSULTING ASSOCIATION OF THE R.O.C.) に招かれ、「個人情報保護法施行細則と金融業による対応の道」と題して講演を行いました。
  24. 【講演活動】 当事務所の盧偉銘弁護士は2012年4月7日、台北律師公会 (Taipei Bar Association) 公司治理及企業併購委員会 (コーポレート・ガバナンスおよび企業買収合併委員会) を主宰し、林國全教授を招きして「金融消費者保護法の初歩的分析」と題してご講演いただきました。
  25. 【公共参加】 当事務所の蔡嘉政弁護士は、台北律師公会 (Taipei Bar Association) 副祕書長に就任しました。
  26. 【講演活動】 当事務所の劉康身弁護士ならびに葉秋英顧問は2011年12月12日、中華民国証券商業同業公会 (Taiwan Securities Association) に招かれ、「個人情報保護法とその施行細則」と題して講演を行いました。
  27. 【公共参加】 当事務所の李師榮弁護士は、台北律師公会 (Taipei Bar Association) 祕書長に就任しました。

Lexgroup Newsletter from Lexcel Partners(Issue No. 288)II
2018-01-23    

 

 
Medical Care Act
 
6.     Amendment to the Medical Care Act
 
On December 29, 2017, the Legislative Yuan passed the amendment to Article 82 of the Medical Care Act with Paragraphs 2 to 4 added.  The amendment provides that the civil liabilities to patients borne by medical personnel as he/she executes medical business arise when they intentionally or negligently fail to exercise necessary duty of care in medical care and reasonable and professional clinic discretion.  The criminal liabilities for death or body injury borne by medical personnel as he/she executes medical business also arise when they fail to exercise necessary duty of care in medical care and reasonable and professional clinic discretion.  When determining whether the professional clinic discretion and duty of care is exercised, the objective circumstances, such as medical normal rules, medical standards, medical equipment, working conditions, and emergencies shall be taken into account.
 
Reported by: Kang-Shen Liu / Chen-Chi Wang
 
Food and Drug Administration
 
7.     New Regulations on Health Food Product Labeling
 
On December 31, 2017, the Legislative Yuan passed three readings of the amendments to the Health Food Control Act, summarized below:
 
(1) If a health food product comprises two or more mixed components, name and weight or volume of each component shall be separately labeled, in an order of contents from greatest to least.
 
(2) The net weight, volume or quantity of the content of a health food product shall be labeled.
 
(3) For a compound food additive with a functional name, the name of each component food additive shall be labeled.
 
(4) Health food products shall be labeled with precautions regarding possible health damage by the products and other necessary warnings.
 
In addition, a new set of Regulations takes effect as of January 1, 2018, requiring health food products be labeled with the following precautions: (1) “This product is for health care and is not a medicine. Patients still need medical treatments.” (for capsule or tablet products); and (2) “Please follow the recommended intake. Do not overdose.”
 
Reported by: Jolene Wang / Crick Liang
 
8.     Amendments to Pharmaceutical Affairs Act
 
On December 29, 2017, the Legislative Yuan passed three readings of the amendments to the Pharmaceutical Affairs Act ("Amendments").  We summarize the main points as follows.
 
(1) To clarify the data exclusivity protection period, being five (5) years, for a new drug of new molecular entity:
 
The languages of the relevant provision are modified to clarify that the absolute data exclusivity protection period for a new drug of a new molecular entity is three (3) years; after expiration of this 3-year period, another pharmaceutical firm may start to apply for marketing approval of drugs of the same components but such (later) marketing approval may not be issued until expiration of five (5) years from the issuance of the (original) marketing approval for the new drug of a new molecular entity.
 
(2) To add the data exclusivity protection period, being three (3) years, for a new drug for a new indication:
 
The data exclusivity protection for a new drug of a new indication is newly added, the absolute protection period for which is two (2) years; after the expiration of this 2-year period, another pharmaceutical firm may start to apply for marketing approval of drugs for the same indication but such (later) marketing approval may not be issued until expiration of five (3) years from the approval of the addition or change of the indication for the drugs.
 
(3) To introduce a patent linkage system:
 
According to the patent linkage system, the holder of marketing approval for a new drug (patentee) shall submit to the Ministry of Health and Welfare ("MOHW") information on patent(s) associated with the new drug, within 45 days of receipt of the marketing approval.
 
A generic drug applicant shall declare, when applying for marketing approval for the generic drug, one of the following: (i) that said patent information has not been filed, (ii) that said patent has expired, (iii) that a marketing approval of the generic drug will be issued after said patent expires, and (iv) that said patent is invalid or will not be infringed upon by the generic drug.  For item (iv), the generic drug applicant shall notify the patentee and MOHW of this matter.
 
It there is suspicion of patent infringement, the patentee can file a patent infringement lawsuit within 45 days of receipt of the notification, and the MOHW shall suspend the issuance of the marketing approval for the generic drug within 12 months, so as to resolve the patent infringement dispute before the generic drug is launched on the market.  The earliest (first) applicant for applying for a marketing approval of the generic drug, who successfully challenges the patent's validity or does not involve patent infringement, can enjoy 12 months of market exclusivity.  This is to encourage pharmaceutical companies to conduct research and development and design around patents.
 
Regarding the provisions of the patent linked system in the amendments, the effective date is to be determined by the Executive Yuan.
 
Reported by: Jolene Wang / Linda Cheng
 
SITE/SICE
 
9.     Amendments to ''Incentive Plan for SITE'' and ''Incentive Plan for Offshore Fund''
 
(1) ''Incentive Plan for SITE''
 
The Financial Supervisory Commission (''FSC'') issued a ruling on January 4, 2018, to relax the criteria for recognition on certain benchmarks, the key points of which we summarize below:
 
(a). Abilities of Investment and Research: Relax the year-by-year decreasing requirement on the percentage of the number of funds or AUM to which the securities investment trust enterprise (''SITE'') makes arrangements for re-consignation or appointment of overseas advisors, after reaching 50%, to 10%.
 
(b). International Allocation: Deletes the previous requirement of an annual growth rate of 10% for certain benchmarks and simply requires them to grow year by year.
 
(c).   The addition of 3 items that may be deemed other contributions, such as a SITE that launches a green fund that invests in Taiwan (including ETF) and accomplishes a significant performance.
 
(2) ''Incentive Plan for Offshore Fund''
 
The FSC issued a ruling on December 28, 2017, to amend the ''Incentive Plan for Offshore Fund'', which we summarized the key points below:
 
(a). Dimension 1: Specify that the master agent and the Taiwan premise established by an offshore fund institution shall have no material violation for a period of 3 years before the date of applying for recognition with the FSC
 
(b). Benchmark 2.4 of Dimension 2: Delete the requirement of an annual growth rate of 10% after an offshore fund institution invests in SITE funds reaching 4 billion NTD, and delete the measure that reaching Benchmark 2.4 can be deemed as being qualified for the Dimension 2
 
(c).   Specify that the remuneration to the sales agents in relation to the recommendation and marketing activities conducted cooperatively by offshore fund institutions, general managers, and sales agents is calculated on the basis of the AUM of funds which accomplishes a significant effect may be deemed as the other contributions
 
Reported by: Jeffrey Liu / Caitlyn Kao
 
10.     Relief on Restrictions on Trading of the Same Objective by Different Investment Accounts
 
On January 2, 2018, the FSC issued a ruling to relax that the restriction on activities, such as reverse investment decision, reverse purchase advice and reverse purchase against the same investment objective, that shall not be made by a fund manager, discretionary investment manager, or personnel who accepts the mandate of qualified institutional investors to provide securities investment analysts for SICE business when such position is concurrently engaged each other, shall not apply to a case where the objective for investment or recommendation is open-ended funds subscribed/redeemed from the securities investment trust enterprise or offshore fund institution.  However, the appropriate analysis basis and full explanations of necessity shall be stated when conducting the above, which shall be reported to the competent authority for recordation afterwards.
 
Reported by: Jeffrey Liu / Edison Tang
 
11.     Financial Supervisory Commission's ruling on Regulations Governing the Conduct of Discretionary Investment Business by Securities Investment Trust Enterprises and Securities Investment Consulting Enterprises
 
On January, 9, 2018, Financial Supervisory Commission issued a ruling to specify the conditions prescribed by the FSC of Paragraph 7, Article 2 and Paragraph 1, Article 10 of Regulations Governing the Conduct of Discretionary Investment Business by Securities Investment Trust Enterprises and Securities Investment Consulting Enterprises, including the requirements for Common Equity Tier 1 Ratio, Tier 1 Capital Ratio, Total Capital Adequacy Ratio, and Credit Rating of the headquarters (for Foreign Bank Branches).
 
Reported by: Jeffery Liu / Rady Lee
 
Securities
 
12.     Expansion of Scope of Foreign Bonds Traded on Securities Firms' Over-the counter Markets
 
On January 8, 2018, the FSC issued a ruling ("Ruling") to amend the interpretation of the “other securities designated by the Commission” in Paragraph 1, Article 5 of “Regulations Governing Securities Trading on the GreTai Securities Market.” We summarize the major points below:
 
(1) Securities firms may engage in repo trade of foreign bonds with non-professional investors. Furthermore, to enhance the protection of such investors, the FSC further qualifies the scope, interest calculation method, and credit rating requirements for such products.
 
(2) An Offshore Banking Unit ("OBU") concurrently engaging in securities propriety trading business shall act in accordance with Securities Exchange Act and applicable laws/regulations, so the Ruling further provides that the trading counterparty for an OBU's structured notes denominated in foreign currency may include professional institutional investors, high net worth investment legal persons, and professional investment legal persons, or funds with total assets more than NTD100 million.
 
Reported by: Jeffrey Liu / Evelyn Shih
 
Banking
 
13.     Amendments to the "Directions Governing Banking Enterprises Operating Foreign Exchange Business", "Regulations Governing Foreign Exchange Business of Banking Enterprises", and "Directions Governing Designated Banks Conducting Foreign Exchange Business through Electronic and Communications Equipment"
 
The Central Bank of Taiwan ("CBC") recently announced the amended "Directions Governing Banking Enterprises Operating Foreign Exchange Business", "Regulations Governing Foreign Exchange Business of Banking Enterprises", and "Directions Governing Designated Banks Conducting Foreign Exchange Business through Electronic and Communications Equipment", and the key points are summarized below:
 
(1) According to Paragraph 2, Article 16 of the "Directions Governing Banking Enterprises Operating Foreign Exchange Business", the "Monthly Report of Digital Foreign Currency Deposit Accounts" shall be submitted after a designated bank commences the business of opening digital foreign exchange deposit accounts via the Internet.
 
(2) Amendments are made to the "Daily Report of Foreign Exchange Positions", "Daily Report of Export and Remittance Transactions", "Daily Report of Import and Remittance Transactions", "Daily Report of Forward Foreign Exchange", "Daily Report of NDF in NTD", "Daily Report of Foreign Debt Balances", and "Trading Report of Foreign Currency in Cash and Travelers Check" under Paragraph 2, Article 16 of the "Directions Governing Banking Enterprises Operating Foreign Exchange Business" and other related explanations.
 
(3) Amendments are made to the "Regulations Governing Foreign Exchange Business of Banking Enterprises" to urge the banks to follow relevant anti-money laundering and countering terrorism financing regulations when processing foreign exchange business, and to the application procedures and compliance matters for the banks to concurrently engage in foreign currency trust business.
 
(4) The "Directions Governing Designated Banks Conducting Foreign Exchange Business through Electronic and Communications Equipment" is promulgated to be followed by the industry to create a favorable digital environment for financial development and enhance financial competitiveness.  Designated banks accepting foreign exchange business which do not involve in NTD settlement or where the settlement amount does not reach NTD500,000 or the equivalent amount through electronic and communications equipment, such business may be processed directly by the bank without any approval from the CBC.
 
Reported by: Stacy Lo/ Jack Tai
 
Editors:
Mike Lu (Partner)
Stacy Lo (Partner)
Jeffrey Liu (Partner)
Kang-Shen Liu (Partner)
David Tsai (Partner)
Counselors:
Echo Yeh
Sue Su
Shih-Jung Lee
Jolene Wang (Lexcel Partners IP)

http://www.ntcma.org.tw/userprofile.asp ̨0.5s TȲ Ͳ http://yumi-girls.org/xinzhuyuanjiao ̨ϽA·Ħ ǰĦ ҈@С ̨Ԯ http://ulife-village.org.tw/search.asp http://geo.giraffe.com.tw/Global.asp ̨ϲӍ http://healthynews.com.tw/function.php http://yumi-girls.org/xinzhuyuanjiao http://www.ljg.com.tw/trackback.php

 
Areas of Practice

Litigations, dispute resolution and relief, cross border and China investment, drafting and negotiation of commercial agreements, corporate establishment and registrations, mergers & acquisitions, labor and employment matters, real estate, regulatory compliance, tax advice, securities transactions, bank financing, insurance, asset management, fair trade law, and intellectual property right related.

Award

Lexcel Partners was enlisted by Legal 500, as one of recommended firms in the areas of "Corporate and M&A", and "Labor" in Taiwan. Mike Lu, Echo Yeh, Sue Su, and David Tsai of Lexcel Partners were recommended.

Lexcel Partners was ranked by Bloomberg as one of top law firms in terms of deal count and quantity for Mergers and Acquisitions in Taiwan.

Lexcel Partners was enlisted by IFLR 1000 (International Financial Law Review) as one of recommended firms in the area of "Capital Market" and "Dispute Resolution" in Taiwan. Mike Lu and Echo Yeh were recommended.

Lexcel Partners was enlisted by Chambers Asia Pacific as one of the leading firms in the areas of "Corporate and M&A" in Taiwan. Echo Yeh and Sue Su were recommended.

Lexcel Partners was enlisted by Asialaw Profiles as one of leading firms in the areas of "Banking& Financial", "Capital Market", "Corporate and M&A", "Dispute Resolution", "Financial Service Compliance" and "Labor" in Taiwan.  Mike Lu, Echo Yeh and Sue Su were recommended.

編輯室的話
書寫是法律人的天職,各種形式的書寫,摘記的、論述的、分析的、翻譯的、符號的、推敲的,法律人在文字中衍繹、歸納、定位、尋求最近到最遠的邊緣,於是我們決定出版,誌念書寫的軌跡。